Phase 1 trial of AK101 in patients with moderate to severe psoriasis

Trial Profile

Phase 1 trial of AK101 in patients with moderate to severe psoriasis

Recruiting
Phase of Trial: Phase I

Latest Information Update: 21 Mar 2018

At a glance

  • Drugs AK-101 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Mar 2018 New trial record
    • 22 Dec 2017 According to an Akeso Biopharma media release, this trial has been launched at the Chinese Academy of Medical Sciences Peking Union Medical College Hospital, and has begun screening and enrolling patients.
    • 11 Oct 2017 According to an Akeso Biopharma media release, China Food and Drug Administration (CFDA) has approved clinical trial application.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top